Olaparib is an oral poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor that induces synthetic lethality in cancers with homologous recombination defects. Olaparib 100 mg bid (intermittent dosing; capsules) plus gemcitabine 600 mg/m 2 is tolerated in advanced solid tumour patients, with no unmanageable/unexpected toxicities.

READ FULL ARTICLE Curated publisher From Mdlinx